Science
Unpredicted binding found between SARS-CoV-2 and hepatitis C drug, telaprevir – Drug Target Review
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Posted: 24 March 2021 | Victoria Rees (Drug Target Review) | No comments yet
Insights into the interaction between telaprevir and the SARS-CoV-2 main protease could aid in future COVID-19 drug design, say scientists.
Scientists have found new, unexpected behaviours when SARS-CoV-2 – the virus that causes COVID-19 – encounters drug inhibitors, which bind to certain components of the virus and block its ability to reproduce.
According to the team, from the US Department of Energy’s Oak Ridge National…
-
Business17 hours agoWhy did Pilbara Minerals shares rocket 50%+ in August?
-
General17 hours agoJournalist seeks big penalty after illegal ABC sacking
-
Noosa News15 hours agoLNP, Greens call for name changes and scrapped seats as Queensland electoral boundaries reviewed
-
General15 hours ago“Shag on a Rock”. India’s embrace of China highlights Australia’s quandary